Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 71335-2093
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-2093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
This text appears to be a graph showing the cumulative percentage of patients and their change in ADCS-ADL scores from baseline while taking Donepezil Hydrochloride 10 mg/day compared to the placebo. The graph displays a 100% cumulative percentage of patients with the horizontal axis showing the change in ADCS-ADL scores, ranging from -10 to 5. The Donepezil Hydrochloride 10 mg/day line is represented by "—e—" and the placebo line is represented by "—o—". However, without further context, it is difficult to provide a more specific description of what the graph is depicting.*
Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
This appears to be a table showing the percentage of patients who improved or worsened while taking Donepezil Hydrochloride 10mg/day or 5mg/day, compared to a placebo. The patients' improvement is measured by the CIBIC-plus Rating. The table includes different levels of improvement (Moderately, Markedly, Minimally) and worsening, as well as a category for "No Change."*
Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
This is a table showing the mean change from baseline in SIB scores after a 3-month drug treatment with either Donepezil Hydrochloride 10 mg/day or placebo. It suggests that there was clinical improvement observed in the Donepezil Hydrochloride group compared to the placebo group.*
Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
The text describes a chart showing the cumulative percentage of patients who took a medicine (Donepazil Hydrochloride 10mg/day) versus a placebo. The chart also shows the SIB (Severe Impairment Battery) change from baseline. There are percentages shown on the chart ranging from 5 to 100 and time increments of 15, 30, 45, 50, and 75.*
Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
Chemical Structure (Donepezil Str)
Label (Lbl713352093)
This appears to be a label for a Donepezil medication manufactured by Rising Pharma Holdings Inc. The medication is in the form of a white, round tablet with the marking "X;11" on it. It is intended to treat Dachaged and is comparable to Aricept 5mg tablets. The medication should be stored at room temperature and kept out of reach of children. The label includes information on the quantity, expiration date, NDC number, and manufacturer.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
